Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma
| Autor: | Shunsuke Fujimoto, Noriko Tanaka, Takayo Ota, Takao Yamada, Noriyuki Masuda, Masahiro Fukuoka, Kaoru Matsui |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
Lung Neoplasms medicine.medical_treatment desensitization Case Report Adenocarcinoma of Lung Antineoplastic Agents 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Internal Medicine medicine ROS1 Humans Anaplastic lymphoma kinase Protein Kinase Inhibitors Desensitization (medicine) Liver injury crizotinib Lung Crizotinib biology business.industry C-reactive protein c-ROS oncogene 1 General Medicine Middle Aged medicine.disease medicine.anatomical_structure Chemical and Drug Induced Liver Injury Chronic biology.protein Cancer research Adenocarcinoma 030211 gastroenterology & hepatology business liver injury medicine.drug |
| Zdroj: | Internal Medicine |
| ISSN: | 1349-7235 0918-2918 |
| DOI: | 10.2169/internalmedicine.2554-18 |
| Popis: | Crizotinib has been approved for patients with advanced lung adenocarcinoma harboring rearrangements of the c-ROS-1 (ROS1) and anaplastic lymphoma kinase (ALK) genes. We report a patient with ROS1-rearranged lung adenocarcinoma who developed a crizotinib-induced mixed/cholestatic type of liver injury. The patient discontinued crizotinib after 34 days due to liver toxicity. Twenty-four days later, when transaminases and C reactive protein (CRP) were normalized, crizotinib was resumed using an oral desensitization method. The patient was successfully treated for manageable recurrence of liver injury and has been able to continue the treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|